Перейти к основному содержанию

SCIENTIFIC-PRACTICAL PEER-REVIEWED MONTHLY JOURNAL.
INSTITUTION OF MINISTRY OF PUBLIC HEALTH OF THE REPUBLIC OF BELARUS

COMBINED AND MULTIMODAL TREATMENT FOR GLIOBLASTOMA PATIENTS USING INTRAOPERATIVE CHEMOTHERAPY

Objective. Evaluating the intraoperative Cisplacel chemotherapy efficacy in managing grade IV glioblastoma patients the criteria being the progression-free survival and overall survival values allowing for the prognostic factors.

Materials and methods. 445 patients with brain glioblastoma aged 16 to 78 years and Karnofsky performance status ³50% having received postoperative radio- or chemoradiotherapy with Temozolomide after surgical intervention,
51 (11.5%) of them having been administered intraoperative local Cisplacel chemotherapy.

Results. The uni- and multivariate analyses have demonstrated that intraoperative Cisplacel chemotherapy is an independent prognostic factor affecting the survival of patients enrolled in the study only when they age <54 years and there are no signs of a residual tumor after the surgical treatment. Cisplacel administration in this group of patients has made it possible achieve a statistically significant improvement of the median, 1-, 3- and 5-year progression-free survival from 12±1.08 months, 50.9±5.2%, 10.7±3.3%, and 9.2±3.2% to 25±7.04 months, 75.0±10.8%, 23.4±11.6%, and 23.4±11.6%, respectively (Р=0.032); and the median, 1-, 3- и 5-year overall survival from 18±1.27 months, 79.6±4.2%, 19.9±4.3%, and 9.9±3.3% to 35±14.10 months, 100±6.4%, 45.0±13.2%, and 23.5±11.3%, respectively (Р=0.048).

Conclusion. Intraoperative Cisplacel chemotherapy allows improve the treatment outcomes in glioblastoma patients aged <54 years having no signs of a residual tumor after a surgical treatment.